DC
Therapeutic Areas
Verastem Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Avutometinib + Defactinib | KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Approved |
| Avutometinib + Sotorasib | KRAS G12C-Mutant NSCLC | Phase 1/2 |
| Avutometinib + Adagrasib | KRAS G12C-Mutant NSCLC | Phase 1/2 |
| Avutometinib (VS-6766) | RAS Pathway-Driven Cancers (Various Combinations) | Preclinical |
| Defactinib | RAS Pathway-Driven Cancers (in combination) | Phase 1/2 |